NYSEAMERICAN:AMPE Ampio Pharmaceuticals (AMPE) Stock Forecast, Price & News $0.30 -0.01 (-3.23%) (As of 05:31 PM ET) Add Compare Share Share Today's Range$0.28▼$0.3250-Day Range$0.20▼$0.3152-Week Range$0.18▼$3.94Volume171,828 shsAverage Volume283,187 shsMarket Capitalization$4.48 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) StockAmpio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.Read More Receive AMPE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMPE Stock News HeadlinesJune 3, 2023 | finance.yahoo.comAMPE - Ampio Pharmaceuticals, Inc.May 28, 2023 | americanbankingnews.comAmpio Pharmaceuticals (NYSE:AMPE) Now Covered by StockNews.comJune 6, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 26, 2023 | finance.yahoo.comAmpio Pharmaceuticals Announces Series D Preferred Stock Dividend to its Holders of Common StockMay 15, 2023 | americanbankingnews.comInsider Buying: Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) Director Purchases $11,000.00 in StockApril 28, 2023 | americanbankingnews.comAmpio Pharmaceuticals (NYSE:AMPE) Research Coverage Started at StockNews.comApril 22, 2023 | americanbankingnews.comAmpio Pharmaceuticals (NYSE:AMPE) Earns Sell Rating from Analysts at StockNews.comApril 18, 2023 | seekingalpha.comAmpio stock jumps ~20% after CEO letter on drug program, reorganizationJune 6, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.April 14, 2023 | americanbankingnews.comAmpio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.comApril 14, 2023 | americanbankingnews.comAmpio Pharmaceuticals (NYSEAMERICAN:AMPE) Now Covered by Analysts at StockNews.comApril 14, 2023 | americanbankingnews.comAmpio Pharmaceuticals (NYSEAMERICAN:AMPE) Now Covered by StockNews.comApril 13, 2023 | americanbankingnews.comAmpio Pharmaceuticals (NYSEAMERICAN:AMPE) Earns Sell Rating from Analysts at StockNews.comApril 12, 2023 | americanbankingnews.comAmpio Pharmaceuticals (NYSEAMERICAN:AMPE) Coverage Initiated by Analysts at StockNews.comApril 11, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)April 9, 2023 | americanbankingnews.comAmpio Pharmaceuticals (NYSEAMERICAN:AMPE) Coverage Initiated at StockNews.comApril 6, 2023 | americanbankingnews.comAmpio Pharmaceuticals (NYSEAMERICAN:AMPE) Receives New Coverage from Analysts at StockNews.comApril 4, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Ampio Pharmaceuticals (NYSEAMERICAN:AMPE)April 3, 2023 | thestreet.comAmpio Too Busy to Tell Investors Results of Eye Drug StudyFebruary 9, 2023 | thestreet.comWhy Ampio Pharmaceuticals (AMPE) Stock Is Plummeting TodayFebruary 7, 2023 | wsj.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Ampio Pharmaceuticals, Inc.December 27, 2022 | finance.yahoo.comAmpio Pharmaceuticals Regains Compliance with NYSE American Continued Listing StandardsNovember 17, 2022 | finance.yahoo.comAmpio Pharmaceuticals Announces NYSE American Removal of Trading SuspensionNovember 8, 2022 | finance.yahoo.comAmpio Pharmaceuticals Announces Fifteen-to-One Reverse Stock SplitOctober 16, 2022 | stockhouse.comMONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmOctober 16, 2022 | prnewswire.comAMPE DEADLINE TOMORROW: ROSEN, skilled investor counsel, Encourages Ampio Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important October 17 Deadline in Securities Class Action - AMPEOctober 12, 2022 | benzinga.comMONDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Ampio Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSee More Headlines AMPE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMPE Company Calendar Last Earnings5/08/2023Today6/06/2023Next Earnings (Estimated)8/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNYSEAMERICAN:AMPE Previous SymbolNYSE:AMPE CUSIP03209T10 CIK1411906 Webampiopharma.com Phone(720) 437-6500Fax720-437-6501Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.8493) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,080,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-97.46% Return on Assets-69.15% Debt Debt-to-Equity RatioN/A Current Ratio4.67 Quick Ratio4.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.02 per share Price / Book0.15Miscellaneous Outstanding Shares15,093,000Free Float14,960,000Market Cap$4.48 million OptionableOptionable Beta1.48 Key ExecutivesMichael A. MartinoChief Executive Officer & DirectorDaniel G. StokelyChief Financial Officer & SecretaryHoward LevyChief Medical OfficerLane HapkeVice President-Manufacturing OperationsLaura GoldbergVice President-Quality & Regulatory OperationsKey CompetitorsAcura PharmaceuticalsOTCMKTS:ACURLexaria BioscienceNASDAQ:LEXXTimber PharmaceuticalsNYSE:TMBRSonoma PharmaceuticalsNASDAQ:SNOAKiora PharmaceuticalsNASDAQ:KPRXView All CompetitorsInsiders & InstitutionsMichael A MartinoBought 76,890 shares on 5/24/2023Total: $22,298.10 ($0.29/share)HRT Financial LPBought 202,574 shares on 5/12/2023Ownership: 1.438%David R StevensBought 50,000 shares on 5/11/2023Total: $11,000.00 ($0.22/share)View All Insider TransactionsView All Institutional Transactions AMPE Stock - Frequently Asked Questions How have AMPE shares performed in 2023? Ampio Pharmaceuticals' stock was trading at $0.2252 at the start of the year. Since then, AMPE shares have increased by 31.8% and is now trading at $0.2968. View the best growth stocks for 2023 here. When is Ampio Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023. View our AMPE earnings forecast. How were Ampio Pharmaceuticals' earnings last quarter? Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) announced its quarterly earnings results on Monday, May, 8th. The specialty pharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter. What other stocks do shareholders of Ampio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ampio Pharmaceuticals investors own include Trevena (TRVN), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Rigel Pharmaceuticals (RIGL), Cogent Biosciences (UMRX), ADMA Biologics (ADMA), Great Panther Mining (GPL), Zosano Pharma (ZSAN) and Miragen Therapeutics (MGEN). What is Ampio Pharmaceuticals' stock symbol? Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE." Who are Ampio Pharmaceuticals' major shareholders? Ampio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include HRT Financial LP (1.44%). Insiders that own company stock include Dan Stokely, David R Stevens, Holli Cherevka, Michael A Martino and Philip H Coelho. View institutional ownership trends. How do I buy shares of Ampio Pharmaceuticals? Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ampio Pharmaceuticals' stock price today? One share of AMPE stock can currently be purchased for approximately $0.30. How much money does Ampio Pharmaceuticals make? Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) has a market capitalization of $4.48 million. The specialty pharmaceutical company earns $-17,080,000.00 in net income (profit) each year or ($1.8493) on an earnings per share basis. How can I contact Ampio Pharmaceuticals? Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The official website for the company is ampiopharma.com. The specialty pharmaceutical company can be reached via phone at (720) 437-6500, via email at info@ampiopharma.com, or via fax at 720-437-6501. This page (NYSEAMERICAN:AMPE) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ampio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.